Loading…
Vyepti is a brand name for Eptinezumab. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: VYEPTI is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
Verbatim from this product's EMA label. Tap a section to expand.
The treatment should be initiated by a healthcare professional experienced in the diagnosis and treatment of migraine. The infusion of VYEPTI should be initiated and supervised by a healthcare professional. 3 Posology The recommended dose is 100 mg administered by intravenous infusion every 12 weeks.
1). The need for dose escalation should be assessed within 12 weeks after initiation of the treatment. When switching dosage, the first dose of the new regimen should be given on the next scheduled dosing date. Overall benefit and continuation of treatment should be assessed 6 months after initiation of the treatment.
Any further decision to continue the treatment should be made on an individual patient basis. Special Populations Elderly (aged 65 years and over) There is limited data available for the use of VYEPTI in patients ≥65 years of age. No dose adjustment is required in the elderly patients as the pharmacokinetics of eptinezumab were not affected by age.
2). Paediatric population The safety and efficacy of VYEPTI in children aged 6 to 18 years has not yet been established. Currently no data are available. There is no relevant use of VYEPTI in children below the age of 6 years for the prophylaxis of migraine.
Method of administration VYEPTI is for intravenous use only after dilution. 6. Following dilution, infuse VYEPTI over approximately 30 minutes. The treating healthcare professional should observe or monitor patients during and after the infusion in accordance with normal clinical practice.
Do not administer VYEPTI as a bolus injection.
Summary of the safety profile Over 5 900 patients have been treated with VYEPTI in clinical studies. Of these, approximately 3 000 patients have been exposed for at least 6 months and 1 600 exposed for at least 1 year. Common adverse reactions in the placebo-controlled clinical studies for the preventive treatment of migraine were hypersensitivity and infusion-related reactions (see below).
Most hypersensitivity reactions occurred during infusion and were not serious. Infusion site related adverse events occurred infrequently and in similar proportions of VYEPTI and placebo patients (< 1%) with no apparent relationship to VYEPTI dose.
5% of VYEPTI and placebo patients. Tabulated list of adverse reactions Adverse reactions from clinical trials and post-marketing experience (table 1) are classified by MedDRA system organ classification and frequency. Frequencies have been evaluated according to the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000).
4). The reported anaphylactic reactions have included symptoms of hypotension and respiratory difficulties, and have led to discontinuation of VYEPTI. In clinical studies, other hypersensitivity reactions, including angioedema, urticaria, flushing, rash and pruritus, were reported in approximately 4% and 3% of patients on the 300 mg and 100 mg dose, respectively, and 2% of patients on placebo (saline).
Other symptoms reported in association with eptinezumab infusion include respiratory symptoms (nasal congestion, rhinorrhea, throat irritation, cough, sneezing, dyspnea) and fatigue (see below). Most of these events were non-serious and transient in nature.
6 Fatigue Approximately 3% of patients on eptinezumab and 2% of patients on placebo in the placebo- controlled clinical trials experienced fatigue. Fatigue was most frequent on the day of the first infusion. Following the first week and with subsequent infusions, fatigue was reported in lower incidences and the incidences were comparable to placebo.
Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded. g. 1). Limited safety data are available in patients with cardiovascular disease and/or cardiovascular risk factors such as diabetes, circulatory diseases and hyperlipidaemia.
Patients with a history of neurological diseases or patients with psychiatric conditions that were uncontrolled and/or untreated were excluded from the clinical studies. Limited safety data are available in these patients. Serious hypersensitivity Serious hypersensitivity reactions, including anaphylactic reactions, have been reported and may develop within minutes of the infusion.
8). If a serious hypersensitivity reaction occurs, administration of VYEPTI should be discontinued immediately and appropriate therapy initiated. If the hypersensitivity reaction is not serious, continuation of further treatment with VYEPTI is up to the discretion of the treating physician, taking into account the benefit-risk for the individual patient.
Excipients VYEPTI contains sorbitol (E420). Patients with hereditary fructose intolerance (HFI) must not be given this medicinal product unless strictly necessary. A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in European Union? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
3% respectively. The ADAs peaked at week 24 and thereafter showed a steady decline even after subsequent dosing every 12 weeks. In the long-term, repeat dose studies with treatment durations of at least 1 year, the incidence of ADAs and NAbs ranged from 18% - 21% and 4% - 7%, respectively.
In PREVAIL where patients received up to 8 infusions, ADAs developed in 18% of patients and NAbs developed in 7% of patients. 3% of patients were ADA positive at week 48, 4% were ADA positive at week 72, and all patients, except one patient lost to follow up, were ADA negative at week 104 (the last assessment in the study).
In the clinical studies, eptinezumab trough plasma concentrations appeared lower in patients who developed anti-eptinezumab antibodies. There was no evidence of impact of anti-eptinezumab antibody development on efficacy or safety in clinical studies.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.